← ANALYST RATINGS · TIPRANKS
Fresenius Medical Care (FMS): analyst forecast and price target
Analyst consensus
Hold0 Buy1 Hold0 Sell
Ratings of 1 analysts in the last 3 months · top analysts only12-month forecast
Based on 1 price targets given in the last 3 months, the average target is $24.00, the highest $24.00, the lowest $24.00. The average is +8.3% from the last price of $22.17.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| David S Macdonald★★★★★★★★★★#400 · hits 63% · avg +13.2% | Truist Financial | $25.00 → $24.00−4.0% | Hold | +8.3% | Reiterated | 12.10.26on TipRanks 07:55 | +0.8%next day −0.6% | ↗ |
| AI xAi Medical - Care FacilitiesxAI Grok-4 | TipRanks - xAI | $27.00 → $23.00−14.8% | Buy | +3.7% | Reiterated | 08.10.26on TipRanks 14:05 | — | |
| AI DeepSeek Medical - Care FacilitiesDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $27.00 → $22.00−18.5% | Hold | −0.8% | Downgrade | 08.10.26on TipRanks 14:05 | — | |
| AI OpenAI Medical - Care FacilitiesOpenAI 5.2 | TipRanks - OpenAI | $26.00 → $21.50−17.3% | Hold | −3.0% | Reiterated | 08.10.26on TipRanks 14:05 | — | |
| AI Anthropic Medical - Care FacilitiesAnthropic Opus-4.6 | TipRanks - Anthropic | $24.50 → $21.00−14.3% | Hold | −5.3% | Reiterated | 08.10.26on TipRanks 14:05 | — | |
| AI Google Medical - Care FacilitiesGemini 3.1Pro | TipRanks - Google | $27.00 → $23.00−14.8% | Buy | +3.7% | Reiterated | 08.10.26on TipRanks 14:05 | — | |
| AI PerPlexity Medical - Care FacilitiesPerPlexity SonarPro | TipRanks - PerPlexity | $27.00 → $23.00−14.8% | Buy | +3.7% | Reiterated | 08.10.26on TipRanks 14:05 | — | |
| Susannah Ludwig★★★★★★★★★★#11190 · hits 36% · avg −5.7% | Bernstein | $25.50 → $25.80+1.2% | Hold | +16.4% | Reiterated | 06.08.26on TipRanks 08:11 | +1.0%next day +0.1% · 5 days −3.2% | ↗ |
| Hugo Solvet★★★★★★★★★★#9944 · hits 55% · avg −5.2% | Exane BNP Paribas | $19.90 | Sell | −10.2% | Downgrade | 28.07.26on TipRanks 04:40 | −0.7%next day +2.0% · 5 days −7.1% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Fresenius Medical Care
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 12.10.26: target $23.23 at a price of $21.06 (+10.3%); now: $23.23 at $22.17 (+4.8%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 03.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.60 (from $0.53 to $0.70). Last quarter: $0.65.
Sales
Next quarter’s sales estimate — $5.6B (from $5.4B to $5.8B). Last quarter: $5.7B.
Best top-analyst consensus in the sector · Healthcare
About Fresenius Medical Care
- CEO: Helen Giza
- Employees: 108,165
- Else-KrOener Strasse 1, Bad Homburg, HE, 61352, DE
- www.freseniusmedicalcare.com
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughl
Data from the stock’s TipRanks forecast page, read 115 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗